Sweden's ChemoTech Q1 net sales rise, loss narrows on US operation improvement

About this update from Scandinavian Chemotech Ab Class B

OverviewSweden medical technology firm's Q1 net sales rose yr/yr, marking its strongest first quarterQ1 loss after financial items narrowed compared to prior yearCompany surpassed 50 installed systems globally during the quarterOutlookCompany prioritizes expansion in North America and Central Europe through sales staff trainingChemoTech expects recurring revenues from treatment kits to improve predictability and long-term valueCompany maintains focus on disciplined execution, operational efficiency, and sustainable growthResult DriversSALES PROCESS IMPROVEMENTS - Co said operational improvements and strengthened sales processes, especially in the U.S., contributed to more reliable revenue generationANIMAL CARE ADOPTION - Increased adoption of vetIQure and Tumour Specific Electroporation (TSE) among clinics supported revenue growthRECURRING REVENUE - Higher share of revenue from recurring treatment kit sales improved predictability and long-term value creationCompany press release:Key DetailsMetricBeat/MissActualConsensus EstimateQ1 SalesSEK 2.80 mlnQ1 EPS-SEK 0.06Q1 Operating Cash Flow-SEK 1.14 mlnAnalyst CoverageWall Street's median 12-month price target for Scandinavian ChemoTech AB is SEK6.30, about 58.7% above its April 27 closing price of SEK3.97For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

View stock analysis, news, and events for Scandinavian Chemotech Ab Class B